Abbott, AstraZeneca cholesterol combo
Executive Summary
Abbott and AstraZeneca have decided to pursue development of a combination of Abbott's next-generation fenofibrate ABT-335 with AstraZeneca's Crestor (rosuvastatin), the firms announce Aug. 31. The partnership to develop a multi-targeted fenofibrate/statin cholesterol combination was announced last year. However, the companies had not determined whether the product would use the investigational ABT-335 or Abbott's marketed drug, TriCor (fenofibrate). Abbott and AstraZeneca are targeting 2009 for submitting an NDA for the combination, which is expected to offer the LDL-C lowering benefits of Crestor and the HDL-C raising and triglyceride-lowering benefits of fibrates. Based on positive clinical trial results, Abbott also said it will file ABT-335 as monotherapy by year-end...
You may also be interested in...
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.